Double-blind test on the efficacy of methylcobalamin on sleep-wake rhythm disorders.
The therapeutic effect of methylcobalamin (Met-12) on sleep-wake rhythm disorders was examined in a double-blind test. In the test group which was given a large dosage, a higher percentage of improvement was found compared to the control group with a small dosage, although the difference was not significant. The test group inconsistently showed significant improvement in both the sleep-wake cycle parameters and in clinical symptoms. The tendency was for the results to show a beneficial effect of Met-12 on rhythm disorders. However, because the percentage of improvement was low and significant improvement was inconsistent, Met-12 might be considered to have a low therapeutic potency and possible use as a booster for other treatment methods of the disorders.
Takahashi
K
K
National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Okawa
M
M
Matsumoto
M
M
Mishima
K
K
Yamadera
H
H
Sasaki
M
M
Ishizuka
Y
Y
Yamada
K
K
Higuchi
T
T
Okamoto
N
N
Furuta
H
H
Nakagawa
H
H
Ohta
T
T
Kuroda
K
K
Sugita
Y
Y
Inoue
Y
Y
Uchimura
N
N
Nagayama
H
H
Miike
T
T
Kamei
K
K
D000339:Affect / Q000187:drug effects; D001143:Arousal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D012894:Sleep Stages / Q000187:drug effects*; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014851:Wakefulness / Q000187:drug effects*
C019476:mecobalamin; D014805:Vitamin B 12